The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical interest in the human intestinal microbiota has increased considerably. However, an overview of clinical studies investigating the link between the human intestinal microbiota and systemic cancer therapy is lacking. This systematic review summarizes all clinical studies describing the association between baseline intestinal microbiota and systemic cancer therapy outcome as well as therapy-related changes in intestinal microbiota composition. A systematic literature search was performed and provided 23 articles. There were strong indications for a close association between the intestinal microbiota and outcome of immunotherapy. Furthermore, the development of chemotherapy-induced infectious complications seemed to be associated with the baseline microbiota profile. Both chemotherapy and immunotherapy induced drastic changes in gut microbiota composition with possible consequences for treatment efficacy. Evidence in the field of hormonal therapy was very limited. Large heterogeneity concerning study design, study population, and methods used for analysis limited comparability and generalization of results. For the future, longitudinal studies investigating the predictive ability of baseline intestinal microbiota concerning treatment outcome and complications as well as the potential use of microbiota-modulating strategies in cancer patients are required. More knowledge in this field is likely to be of clinical benefit since modulation of the microbiota might support cancer therapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 10×
“(2018), [25] Metastatic melanoma n = 43 Anti-PD-1 16S rRNA gene sequencing Response (n = 30) ↑ α-diversity (inverse Simpson score) ↑ between-group β-diversity ↑ Clostridiales ↑ Ruminococcaceae ↑ Faecalibacterium ↓ Bacteroidales”
BackgroundInfluentialAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 12×
“(2015), [41] Metastatic melanoma n = 18 Ipilimumab See Chaput et al.”
BackgroundMethodResultInfluentialRinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Microorganisms · doi:10.3390/microorganisms7010014 · Cited by 3,462 · cited 2×
“Strong confounding factors in this field are antibiotic use, age, BMI, and diet [62].”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 10×
“As conclusions did not change when removing the four anti-CTLA-4 treated patients, these patients were retained in the analysis [24].”
BackgroundMethodInfluentialKostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718 · cited 2×
“Similarly, abundance of Fusobacterium nucleatum has been found to be increased in colorectal cancer and it is suggested that this bacterial species might be involved in intestinal tumorigenesis and modulation of the tumor microenvironment [10,11].”
BackgroundRound, J. L., & Mazmanian, S. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909122107 · Cited by 2,233 · cited 9×
“There are indications that anti-PD-1 therapy stimulates T-cell responses against intestinal bacteria and consequently improves cancer cell surveillance and detection [26,58].”
BackgroundInfluentialThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic, A. D., Gevers, D., Pedamallu, C. S., Michaud, M., Duke, F., Earl, A. M., Ojesina, A. I., Jung, J., Bass, A. J., Tabernero, J., et al. (2012) · Genome Research · doi:10.1101/gr.126573.111 · Cited by 1,960
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Vandeputte, D., Falony, G., Vieira-Silva, S., Tito, R. Y., Joossens, M., & Raes, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309618 · Cited by 1,028 · cited 1×
“(2016) showed that stool consistency was strongly associated with microbiota richness as well as with community composition and abundance of specific enterotypes [65].”
BackgroundDubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 10×
“…prausnitzii ↑ Holdemania filiformis ↑ Bacteroides thetaiotamicron n = 13 Pembrolizumab Metagenomic shotgunsequencing Response (n = 6) ↑ Dorea formicigenerans Dubin et al. (2016), [29] Metastatic Melanoma n = 34 Ipilimumab 16S rRNA gene sequencing Colitis free ↑ Bacteroidaceae ↑ Bacteroides ↑…”
BackgroundInfluentialGut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970 · cited 6×
“In this context, Alexander et al. (2017) suggested the TIMER mechanistic framework (translocation, immunomodulation, metabolism, enzymatic degradation, reduced diversity) to describe the mechanisms through which the gut microbiota might modulate chemotherapy treatment [45].”
BackgroundInfluentialFrankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709
Flores, R., Shi, J., Fuhrman, B., Xu, X., Veenstra, T. D., Gail, M. H., Gajer, P., Ravel, J., & Goedert, J. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-253 · Cited by 615 · cited 2×
“It has been suggested that gut bacteria affect the development of breast cancer through modulation of estrogen m tabolism [12,13].”
BackgroundVerdam, F. J., Fuentes, S., de Jonge, C., Zoetendal, E. G., Erbil, R., Greve, J. W., Buurman, W. A., de Vos, W. M., & Rensen, S. S. (2013) · Obesity · doi:10.1002/oby.20466 · Cited by 587
Self-citationChapter 12: Human Microbiome Analysis
Morgan, X. C., & Huttenhower, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002808 · Cited by 496 · cited 4×
“β-diversity defines the number of taxa shared between different samples and can be seen as a (dis)similarity score [7].”
BackgroundInfluentialBreast cancer in postmenopausal women is associated with an altered gut metagenome
Zhu, J., Liao, M., Yao, Z., Liang, W., Li, Q., Liu, J., Yang, H., Ji, Y., Wei, W., Tan, A., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0515-3 · Cited by 377
Fuhrman, B. J., Feigelson, H. S., Flores, R., Gail, M. H., Xu, X., Ravel, J., & Goedert, J. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2222 · Cited by 339 · cited 1×
“Assuming that hormonal therapy interacts with the intestinal microbiota involved in steroid/hormone synthesis, this might modulate steroid biosynthesis, thereby affecting systemic hormone levels and therapy efficacy [12,60,61].”
BackgroundRidlon, J. M., Ikegawa, S., Alves, J. M. P., Zhou, B., Kobayashi, A., Iida, T., Mitamura, K., Tanabe, G., Serrano, M., De Guzman, A., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038869 · Cited by 319 · cited 1×
“Assuming that hormonal therapy interacts with the intestinal microbiota involved in steroid/hormone synthesis, this might modulate steroid biosynthesis, thereby affecting systemic hormone levels and therapy efficacy [12,60,61].”
BackgroundThe Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes
Alberto González-Regueiro, J., Moreno-Castañeda, L., Uribe, M., & Carlos Chávez-Tapia, N. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5494 · Cited by 247
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
Roberts, A. B., Wallace, B. D., Venkatesh, M. K., Mani, S., & Redinbo, M. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085852 · Cited by 140
Deng, X., Li, Z., Li, G., Li, B., Jin, X., & Lyu, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01607 · Cited by 114
Cited by
Gut microbiota and short‐chain fatty acid alterations in cachectic cancer patients
Ubachs, J., Ziemons, J., Soons, Z., Aarnoutse, R., van Dijk, D. P. J., Penders, J., van Helvoort, A., Smidt, M. L., Kruitwagen, R. F. P. M., Baade‐Corpelijn, L., et al. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12804 · Cited by 161
Self-citationMetaproteomics in the One Health framework for unraveling microbial effectors in microbiomes
Heyer, R., Wolf, M., Benndorf, D., Uzzau, S., Seifert, J., Grenga, L., Pabst, M., Schmitt, H., Mesuere, B., Van Den Bossche, T., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02119-5 · Cited by 22
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine
Aarnoutse, R., Ziemons, J., de Vos-Geelen, J., Valkenburg-van Iersel, L., Wildeboer, A. C. L., Vievermans, A., Creemers, G.-J. M., Baars, A., Vestjens, H. J. H. M. J., Le, G. N., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.10.004 · Cited by 19
Self-citation
Metadata
- Authors
- Aarnoutse, R., Ziemons, J., Penders, J., Rensen, S. S., de Vos-Geelen, J., & Smidt, M. L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-08-25
- Volume
- 20
- Issue
- 17
- Pages
- 4145
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2969329470
- Cited by
- 83
- References
- 27
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.